Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 3/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7821908 | 0.87 | SRC (0.55) | SRCCYP2D6LMNAMAPK1SMN1; SMN2 | |
| SCHEMBL20582610 | 0.84 | SRC (0.50) | SRCCYP2D6HSD11B1LMNATSHR | |
| SCHEMBL8451353 | 0.84 | SRC (0.50) | SRCCYP2D6HSD11B1LMNAMAPK1 | |
| SCHEMBL13112961 | 0.83 | SRC (0.50) | SRCCYP2D6LMNAMAPK1TSHR | |
| SCHEMBL4801312 | 0.81 | SRC (0.47) | SRCCYP2D6HSD11B1LMNAMAPK1 | |
| SCHEMBL12891199 | 0.81 | POLB (0.60) | TSHRMMP1MMP9MMP13ALDH1A1 | |
| SCHEMBL20869602 | 0.78 | SRC (1.00) | SRCCYP2D6LMNAMAPK1CYP2C19 | |
| SCHEMBL11166146 | 0.78 | SRC (1.00) | SRCCYP2D6LMNAMAPK1CYP2C19 | |
| SCHEMBL9912818 | 0.78 | SRC (1.00) | SRCCYP2D6LMNAMAPK1CYP2C19 | |
| SCHEMBL5016643 | 0.77 | SRC (0.96) | SRCCYP2D6LMNAMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10688080-B2 | Compositions, methods of use, and methods of treatment | UNIVERSITY OF SOUTH FLORIDA (US) | 2020-06-23 | — | — | US | disclosed |
| US-10688080-B2 | Compositions, methods of use, and methods of treatment | UNIVERSITY OF SOUTH FLORIDA (US) | 2020-06-23 | — | — | US | disclosed |
| US-20180333390-A1 | COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT | UNIVERSITY OF SOUTH FLORIDA | 2018-11-22 | — | — | US | disclosed |
| US-4490524-A | BACTERICIDES | TOYO JOZO KABUSHIKI KAISHA (JP) | 1984-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10688080-B2 | Compositions, methods of use, and methods of treatment | LIPA, LCT, GAA | SRC 3040/4885CYP2D6 607/4885HSD11B1 1059/4885 |
| US-20180333390-A1 | COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT | LIPA, LCT, GAA | SRC 3040/4885CYP2D6 607/4885HSD11B1 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.